Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2018 1
2019 1
2020 5
2021 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
RAS-targeted therapies: is the undruggable drugged?
Moore AR, Rosenberg SC, McCormick F, Malek S. Moore AR, et al. Nat Rev Drug Discov. 2020 Aug;19(8):533-552. doi: 10.1038/s41573-020-0068-6. Epub 2020 Jun 11. Nat Rev Drug Discov. 2020. PMID: 32528145 Free PMC article. Review.
Spliceosomal disruption of the non-canonical BAF complex in cancer.
Inoue D, Chew GL, Liu B, Michel BC, Pangallo J, D'Avino AR, Hitchman T, North K, Lee SC, Bitner L, Block A, Moore AR, Yoshimi A, Escobar-Hoyos L, Cho H, Penson A, Lu SX, Taylor J, Chen Y, Kadoch C, Abdel-Wahab O, Bradley RK. Inoue D, et al. Among authors: moore ar. Nature. 2019 Oct;574(7778):432-436. doi: 10.1038/s41586-019-1646-9. Epub 2019 Oct 9. Nature. 2019. PMID: 31597964 Free PMC article.
RAS-targeted therapies.
Moore AR, Rosenberg SC, McCormick F, Malek S. Moore AR, et al. Nat Rev Drug Discov. 2021 May 14. doi: 10.1038/s41573-021-00220-6. Online ahead of print. Nat Rev Drug Discov. 2021. PMID: 33990767 No abstract available.
ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer.
Li D, Zhan Y, Wang N, Tang F, Lee CJ, Bayshtok G, Moore AR, Wong EWP, Pachai MR, Xie Y, Sher J, Zhao JL, Khudoynazarova M, Gopalan A, Chan J, Khurana E, Shepherd P, Navone NM, Chi P, Chen Y. Li D, et al. Among authors: moore ar. Sci Adv. 2023 Apr 5;9(14):eadc9446. doi: 10.1126/sciadv.adc9446. Epub 2023 Apr 5. Sci Adv. 2023. PMID: 37018402 Free PMC article.
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S. Yen I, et al. Among authors: moore ar. Nature. 2021 Jun;594(7863):418-423. doi: 10.1038/s41586-021-03515-1. Epub 2021 May 5. Nature. 2021. PMID: 33953400 Clinical Trial.
The promise and peril of KRAS G12C inhibitors.
Moore AR, Malek S. Moore AR, et al. Cancer Cell. 2021 Aug 9;39(8):1059-1061. doi: 10.1016/j.ccell.2021.07.011. Cancer Cell. 2021. PMID: 34375610 Free article.
Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.
Hitchman TD, Bayshtok G, Ceraudo E, Moore AR, Lee C, Jia R, Wang N, Pachai MR, Shoushtari AN, Francis JH, Guan Y, Chen J, Chang MT, Taylor BS, Sakmar TP, Huber T, Chi P, Chen Y. Hitchman TD, et al. Among authors: moore ar. Clin Cancer Res. 2021 Mar 1;27(5):1476-1490. doi: 10.1158/1078-0432.CCR-20-2860. Epub 2020 Nov 23. Clin Cancer Res. 2021. PMID: 33229459 Free PMC article.
13 results